Atrial functional TR: when is valve-center evaluation appropriate?
A 75-year-old woman with long-standing persistent AF, RA enlargement, and severe TR with preserved RV function. Volume and rate optimization have been completed. This case asks when valve-center evaluation is the next step.
Clinical scenario
75-year-old woman with long-standing persistent AF in outpatient follow-up after a heart failure hospitalization. Volume optimized, rate well controlled, but mild exertional dyspnea and leg edema persist. TTE: severe TR, marked RA enlargement, annular dilation 44 mm, preserved RV function. No device lead, no dominant left-sided valve lesion, no severe pulmonary hypertension. What is driving the TR, and what is the next step?
Atrial functional TR: the dominant mechanism is AF-related RA remodeling and tricuspid annular dilation — not RV dilation or pulmonary hypertension. Optimization is complete. The question is whether valve-center evaluation is now appropriate.
Case presentation
A 75-year-old woman with long-standing persistent AF is seen in outpatient follow-up after a hospitalization for right-sided heart failure. She has been treated with diuretics and her volume status has been optimized. Ventricular rate is well controlled. She continues to report mild exertional dyspnea and intermittent leg edema.
Recent TTE shows severe TR, marked RA enlargement, and tricuspid annular dilation measuring 44 mm. RV systolic function is preserved. There is no transvalvular device lead, no dominant left-sided valve lesion, and no severe pulmonary hypertension identified as a primary driver of TR.
Why this is atrial functional TR
In atrial functional TR, the primary remodeling chamber is the right atrium, not the right ventricle. Long-standing AF leads to RA enlargement and tricuspid annular dilation. The leaflets may be structurally normal, but the annulus becomes too large for reliable coaptation.
That is different from ventricular functional TR, where RV dilation, RV dysfunction, pulmonary hypertension, or left-sided heart disease is the dominant driver. Preserved RV function and the absence of severe pulmonary hypertension or left-sided valve disease support the atrial functional phenotype in this case.
What to optimize first
Before considering valve evaluation, modifiable drivers should be addressed:
- Volume status and venous congestion — diuresis to euvolemia reduces RA pressure and may reduce annular tension
- Ventricular rate control — optimized in this patient
- Rhythm-control feasibility — some patients improve TR burden with rhythm restoration; established RA and annular remodeling may limit response in long-standing AF
- HFpEF context and blood pressure — underlying drivers of right-heart loading
- Renal and hepatic function — to assess venous congestion burden
In this patient, optimization has been completed. Severe TR, annular dilation, and mild symptoms persist. RV function is still preserved — a window for evaluation before advanced RV remodeling develops.
Volume and rate optimization are complete. Severe TR, annular dilation 44 mm, and mild symptoms persist. RV function is preserved. What is the next step?
- 1.Refer to a valve center for evaluation✓ Recommended
Persistent severe TR, annular dilation, and symptoms after optimization justify valve-center evaluation. Preserved RV function is a window — not a reason to defer referral.
- 2.Directly determine whether T-TEER is indicated△ Consider
Transcatheter TR therapies are evolving. Suitability depends on anatomy, symptoms, RV function, and local expertise — this is part of valve-center assessment, not a standalone decision at this stage.
- 3.Continue observation because AF treatment will always resolve TR⚠ Not recommended
AF and volume management matter, but established RA and annular remodeling may not resolve with AF treatment alone. Persistent severe TR with symptoms should not be managed by optimism alone.
Teaching points
- Atrial functional TR is driven by AF, RA enlargement, and tricuspid annular dilation — not primarily by RV dilation or pulmonary hypertension. Treat it as a distinct phenotype.
- Preserved RV function is reassuring, but it does not make severe TR irrelevant. It is a window for evaluation before advanced RV failure develops.
- Optimize volume status, rate/rhythm strategy, and HFpEF context first. Some patients improve; established RA and annular remodeling often does not fully resolve with AF management alone.
- If severe TR, annular dilation, symptoms, or right-heart remodeling persist after optimization, valve-center evaluation is appropriate.
- T-TEER and other transcatheter TR therapies are evolving options. ACC/AHA 2020 does not include a primary guideline pathway recommending T-TEER for atrial functional TR. Suitability must be assessed by a specialized team.
- The TR Intervention Navigator routes this case to the atrial functional TR pathway — distinct from ventricular functional TR and primary structural TR.
Apply this in practice
Use the TR Intervention Navigator — select mechanism: atrial functional TR to see the pathway this case follows.
Open TR Intervention Navigator